| abstract |
The invention relates to the compounds of the formulan nand pharmaceutically acceptable salts thereof, in which :n R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid ; R 1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical ; X 1 and X 3 , independently of one another, are oxygen (-O-) or sulphur (-S-) ; and X 2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical ; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB-4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB-4 receptor antagonism. |